Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs Medpace Holdings Inc — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $36.79 (market cap $2.98B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 5.6× MicroSectors FANG and Innovation 3X Leveraged ETN's market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 4,682,352). Which is the better fit depends on your goals — on Pluang, investors hold MicroSectors FANG and Innovation 3X Leveraged ETN for 19 Days and Medpace Holdings Inc for 14 Days on average.
| FNGU | MEDP | |
|---|---|---|
Market Cap | $2.98B | $16.82B |
Volume | 4,682,352 | 223,093 |
Sector | Leveraged / Inverse | Health |
52-Week High | $37.20 | $630.19 |
52-Week Low | $13.73 | $393.42 |
Typical Hold Time | 19 Days | 14 Days |
Enterprise Value | — | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3x leveraged ETN tracking major tech stocks, trades at $36.62, down 1.56% today. Technical indicators show a bullish trend with strong moving average support, though oscillators remain neutral. The ETN provides triple exposure to tech giants like Nvidia, Meta, and Apple, but carries significant volatility risks as highlighted by recent analysis showing an 87% decline during previous tech sector downturns.
The outlook remains highly speculative given the leveraged structure. While bullish technicals suggest potential upside if tech stocks continue performing, the extreme volatility and historical drawdowns present substantial risk. Investors should weigh the amplified returns against the possibility of rapid losses during market corrections.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
